Neupogen
 |
|
| Clinical data | |
|---|---|
| Trade names | Neupogen, Zarxio, others |
| AHFS/Drugs.com | Monograph |
| Pregnancy category |
|
| Routes of administration |
IV, subQ |
| ATC code | |
| Identifiers | |
|
|
| CAS Number | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| ECHA InfoCard | 100.167.401 |
| Chemical and physical data | |
| Formula | C845H1343N223O243S9 |
| Molar mass | 18802.8 g/mol |
Filgrastim, sold under the brand name Neupogen among others, is a medication used to treat low blood neutrophils due to a number of causes. This includes when it occurs following chemotherapy, radiation poisoning, HIV/AIDS, or is of unknown cause. It may also be used to increase white blood cells for gathering during leukapheresis. It is given either by injection into a vein or under the skin.
Common side effects include fever, cough, chest pain, joint pain, vomiting, and hair loss. Severe side effects include splenic rupture and allergic reactions. It is unclear if use in pregnancy is safe for the baby. Filgrastim is similar to naturally occurring granulocyte colony-stimulating factor (G-CSF).
Filgrastim was approved for medical use in the United States in 1991. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 3.95 to 94.66 USD per dose. In the United Kingdom it cost the NIH about 50.15 pounds per 300 ug dose. In the United States treatment costs more than 200 USD.Biosimilars are available.
Filgrastim is used to treat neutropenia, stimulating the bone marrow to increase production of neutrophils. Causes of neutropenia include chemotherapy and bone marrow transplantation.
...
Wikipedia